Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276003 · ClinicalTrials.gov registry record · Phase 2
INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.
A Phase 2 study of Cancer and Non-Hodgkin's Lymphoma, sponsored by University of New Mexi.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT00276003: Completed Phase 2 study of Cancer and Non-Hodgkin's Lymphoma, sponsored by University of New Mexi.
NCT00276003 is a Phase 2 study of Cancer and Non-Hodgkin's Lymphoma that has completed, run by University of New Mexi. The registered enrollment target is 22 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00276003, a Phase 2 study of Cancer and Non-Hodgkin's Lymphoma, has completed, sponsored by University of New Mexi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
Primary objectives * Assess the response rate in patients with recurrent or refractory B-cell NHL or Hodgkins disease, treated with the combination of the gemcitabine and irinotecan. Secondary objectives * Assess progression free survival in these patients treated with this regimen. * Assess toxicity of this regimen in this group of patients.
Conditions Studied
Interventions
- DRUG Gemcitabine, Irinotecan, Allopurinol.
Study Locations (2)
New Mexico
- Lovelace Sandia Health Systems Dept of Hematology - Albuquerque
- University of New Mexico - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2002-08 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
What the finished NCT00276003 record still lists
NCT00276003 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Gemcitabine, Irinotecan, Allopurinol. is the first listed.
NCT00276003 reports a single indexed study location in New Mexico.
Frequently Asked Questions
What is clinical trial NCT00276003 about?
NCT00276003 is a clinical study titled "INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.". Primary objectives * Assess the response rate in patients with recurrent or refractory B-cell NHL or Hodgkins disease, treated with the combination of the gemcitabine and irinotecan. Secondary objectives * Assess progression free survival in these patients treated with this regimen. * Assess toxi...
What is the current status of trial NCT00276003?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2002-08. Estimated completion is 2005-08.
What conditions does trial NCT00276003 study?
This clinical trial studies the following conditions: Cancer, Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00276003?
The interventions under investigation include: Gemcitabine, Irinotecan, Allopurinol. (DRUG).
Who is sponsoring clinical trial NCT00276003?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00276003 being conducted?
This trial has 2 study locations across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00276003's enrollment target sits among peer trials
22 554th of 615 higher than 59 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia